(Bloomberg) — For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” — one that could send its shares veering sharply in either direction.
If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down,…
Source link
